Publication | Closed Access

Sesamol as a potential candidate for the treatment of hepatic fibrosis, based on its regulation of FXR/LXR axis-mediated inhibition of autophagy through crosstalk between hepatic cells and macrophage

Potential CandidateLiver FibrosisImmunologyHepatic FibrosisCirrhosisInflammationCell AutophagyAutophagyHepatotoxicityHepatology FibrosisFibrosisAutoimmune DiseaseLiver PhysiologyFxr/lxr Axis-mediated InhibitionPharmacologyDrug-induced Liver InjuryHepatologyLiver DiseaseMedicine